Glaukos Co. (NYSE:GKOS) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC cut its stake in Glaukos Co. (NYSE:GKOS) by 97.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,641 shares of the medical instruments supplier’s stock after selling 58,368 shares during the period. Peregrine Capital Management LLC’s holdings in Glaukos were worth $246,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Values First Advisors Inc. bought a new position in shares of Glaukos during the third quarter worth about $25,000. Asset Planning Inc acquired a new position in Glaukos during the 4th quarter valued at about $90,000. Harvest Fund Management Co. Ltd grew its position in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the last quarter. KBC Group NV increased its stake in shares of Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares during the period. Finally, EWA LLC bought a new stake in shares of Glaukos during the third quarter valued at approximately $209,000. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on GKOS. Stifel Nicolaus increased their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. JPMorgan Chase & Co. raised their price target on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Wells Fargo & Company raised their target price on shares of Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $159.42.

Glaukos Trading Up 5.5 %

Glaukos stock opened at $161.30 on Thursday. The firm has a market cap of $8.89 billion, a price-to-earnings ratio of -53.41 and a beta of 1.04. Glaukos Co. has a 1 year low of $83.90 and a 1 year high of $163.71. The firm’s 50 day moving average price is $152.65 and its two-hundred day moving average price is $139.03. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,744 shares of company stock valued at $2,792,151 in the last three months. 6.40% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.